{"id":64050,"date":"2026-04-27T20:53:52","date_gmt":"2026-04-27T12:53:52","guid":{"rendered":"https:\/\/flcube.com\/?p=64050"},"modified":"2026-04-27T20:53:53","modified_gmt":"2026-04-27T12:53:53","slug":"novartis-secures-who-pre-qualification-for-coartem-baby-first-antimalarial-specifically-designed-for-newborns-and-infants-under-5-kg","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64050","title":{"rendered":"Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg"},"content":{"rendered":"\n<p><strong>Novartis AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE: NVS<\/a>) announced that the <strong>World Health Organization (WHO)<\/strong> has granted <strong>pre-qualification (PQ)<\/strong> status to <strong>Coartem\u00ae Baby<\/strong> (artemether\/lumefantrine), the <strong>first and only antimalarial medicine<\/strong> formulated specifically for <strong>newborns and small infants weighing 2\u20135 kg<\/strong>.<\/p>\n\n\n\n<p>Marketed as <strong>Riamet Baby<\/strong> in select regions, the dispersible pediatric formulation was co-developed with the <strong>Medicines for Malaria Venture (MMV)<\/strong> to address a critical gap in malaria treatment for the most vulnerable population\u2014infants under six months\u2014who historically lacked age-appropriate dosing options.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-amp-public-health-significance\">Product &amp; Public Health Significance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Indication<\/strong><\/td><td>Uncomplicated <em>Plasmodium falciparum<\/em> malaria in infants 2\u20135 kg<\/td><\/tr><tr><td><strong>Formulation<\/strong><\/td><td>Dispersible tablet with precise micro-dosing; sweet-tasting for acceptability<\/td><\/tr><tr><td><strong>WHO PQ Status<\/strong><\/td><td>Enables procurement by UN agencies (UNICEF, Global Fund) and national programs<\/td><\/tr><tr><td><strong>Development Partnership<\/strong><\/td><td>Novartis + Medicines for Malaria Venture (MMV)<\/td><\/tr><tr><td><strong>Global Need<\/strong><\/td><td>~10 million malaria cases annually in children &lt;5 years; infants at highest risk of severe outcomes<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novartis-broader-global-health-commitment\">Novartis\u2019 Broader Global Health Commitment<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Malaria Portfolio<\/strong>: Largest in the industry, including <strong>four novel non-artemisinin antimalarial compounds<\/strong> in development to combat rising drug resistance<\/li>\n\n\n\n<li><strong>R&amp;D Investment<\/strong>: ><strong>USD 500 million<\/strong> committed to global health R&amp;D since 2021<\/li>\n\n\n\n<li><strong>Access Legacy<\/strong>: Delivered <strong>over 1.1 billion doses<\/strong> of Coartem since 1999, <strong>majority on a not-for-profit basis<\/strong><\/li>\n\n\n\n<li><strong>Supply Model<\/strong>: Sells Coartem Baby at cost to public-sector buyers in endemic countries<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-amp-humanitarian-impact\">Strategic &amp; Humanitarian Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Equity Advance<\/strong>: Closes a decades-long therapeutic gap\u2014previously, caregivers often split adult tablets, risking under\/over-dosing<\/li>\n\n\n\n<li><strong>Program Integration<\/strong>: PQ status accelerates rollout through national malaria control programs across sub-Saharan Africa and Southeast Asia<\/li>\n\n\n\n<li><strong>Innovation Pipeline<\/strong>: Non-artemisinin candidates (e.g., <strong>ganaplacide\/lumefantrine<\/strong>) aim to provide next-generation tools against artemisinin-resistant strains in the Greater Mekong Subregion<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<p>While commercial revenue from Coartem Baby is minimal due to its access-oriented pricing, the approval reinforces Novartis\u2019 leadership in <strong>responsible innovation<\/strong> and strengthens its partnerships with global health institutions\u2014a strategic asset in ESG-focused investor evaluations and public-sector tender eligibility.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief highlights a public health milestone. Distribution scale-up, real-world effectiveness, and pipeline progression remain subject to funding, regulatory approvals, and epidemiological trends.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis AG (NYSE: NVS) announced that the World Health Organization (WHO) has granted pre-qualification (PQ)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":64051,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[140,865],"class_list":["post-64050","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-novartis","tag-nyse-nvs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novartis AG (NYSE: NVS) announced that the World Health Organization (WHO) has granted pre-qualification (PQ) status to Coartem\u00ae Baby (artemether\/lumefantrine), the first and only antimalarial medicine formulated specifically for newborns and small infants weighing 2\u20135 kg.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64050\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg\" \/>\n<meta property=\"og:description\" content=\"Novartis AG (NYSE: NVS) announced that the World Health Organization (WHO) has granted pre-qualification (PQ) status to Coartem\u00ae Baby (artemether\/lumefantrine), the first and only antimalarial medicine formulated specifically for newborns and small infants weighing 2\u20135 kg.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64050\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-27T12:53:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-27T12:53:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2702-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64050#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64050\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg\",\"datePublished\":\"2026-04-27T12:53:52+00:00\",\"dateModified\":\"2026-04-27T12:53:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64050\"},\"wordCount\":354,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64050#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2702-1.webp\",\"keywords\":[\"Novartis\",\"NYSE: NVS\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64050#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64050\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64050\",\"name\":\"Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64050#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64050#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2702-1.webp\",\"datePublished\":\"2026-04-27T12:53:52+00:00\",\"dateModified\":\"2026-04-27T12:53:53+00:00\",\"description\":\"Novartis AG (NYSE: NVS) announced that the World Health Organization (WHO) has granted pre-qualification (PQ) status to Coartem\u00ae Baby (artemether\\\/lumefantrine), the first and only antimalarial medicine formulated specifically for newborns and small infants weighing 2\u20135 kg.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64050#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64050\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64050#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2702-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2702-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64050#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg - Insight, China&#039;s Pharmaceutical Industry","description":"Novartis AG (NYSE: NVS) announced that the World Health Organization (WHO) has granted pre-qualification (PQ) status to Coartem\u00ae Baby (artemether\/lumefantrine), the first and only antimalarial medicine formulated specifically for newborns and small infants weighing 2\u20135 kg.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64050","og_locale":"en_US","og_type":"article","og_title":"Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg","og_description":"Novartis AG (NYSE: NVS) announced that the World Health Organization (WHO) has granted pre-qualification (PQ) status to Coartem\u00ae Baby (artemether\/lumefantrine), the first and only antimalarial medicine formulated specifically for newborns and small infants weighing 2\u20135 kg.","og_url":"https:\/\/flcube.com\/?p=64050","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-27T12:53:52+00:00","article_modified_time":"2026-04-27T12:53:53+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2702-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64050#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64050"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg","datePublished":"2026-04-27T12:53:52+00:00","dateModified":"2026-04-27T12:53:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64050"},"wordCount":354,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=64050#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2702-1.webp","keywords":["Novartis","NYSE: NVS"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64050#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64050","url":"https:\/\/flcube.com\/?p=64050","name":"Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=64050#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=64050#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2702-1.webp","datePublished":"2026-04-27T12:53:52+00:00","dateModified":"2026-04-27T12:53:53+00:00","description":"Novartis AG (NYSE: NVS) announced that the World Health Organization (WHO) has granted pre-qualification (PQ) status to Coartem\u00ae Baby (artemether\/lumefantrine), the first and only antimalarial medicine formulated specifically for newborns and small infants weighing 2\u20135 kg.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64050#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64050"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=64050#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2702-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2702-1.webp","width":1080,"height":608,"caption":"Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64050#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2702-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64050"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64050\/revisions"}],"predecessor-version":[{"id":64052,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64050\/revisions\/64052"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/64051"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64050"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64050"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}